NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
SN BioScience
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Inspirna, Inc.
Cyteir Therapeutics, Inc.
BeiGene
Sellas Life Sciences Group
Vincerx Pharma, Inc.
AstraZeneca
Mundipharma Research Limited
Xencor, Inc.
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Memorial Sloan Kettering Cancer Center
MacroGenics
AstraZeneca
Fate Therapeutics
Xencor, Inc.
Xencor, Inc.
Incyte Corporation
AbbVie
AbbVie
Incyte Corporation
Gilead Sciences
Spectrum Pharmaceuticals, Inc
Incyte Corporation
AstraZeneca
Abramson Cancer Center at Penn Medicine
Celgene
PharmaMar
Canadian Cancer Trials Group
Daiichi Sankyo
Oncology Institute of Southern Switzerland
Swiss Cancer Institute
Pfizer
Butler Hospital
Masonic Cancer Center, University of Minnesota
University of Kansas Medical Center
Amgen
Beth Israel Deaconess Medical Center
Wake Forest University Health Sciences
Roswell Park Cancer Institute
Amgen
Santa Maria Biotherapeutics
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
Novartis